Author:
Zhou Mei,Luo Jian,Chen Michael,Yang Hong,Learned R. Marc,DePaoli Alex M.,Tian Hui,Ling Lei
Reference58 articles.
1. New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond;Beuers;J Hepatol,2015
2. Targeting bile-acid signalling for metabolic diseases;Thomas;Nat Rev Drug Discovery,2008
3. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial;Neuschwander-Tetri;Lancet,2015
4. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid;Hirschfield;Gastroenterology,2015
5. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease;Mudaliar;Gastroenterology,2013
Cited by
82 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献